Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence

被引:0
|
作者
Dinh, Phong Phan [1 ,2 ]
Ho, Tri Huynh Quang [3 ]
Pham, Hung Manh [1 ,2 ,6 ]
Nguyen, Hai Hoang [4 ]
Ton, Minh That [5 ]
Tran, Giang Song [1 ]
Vu, Nga Quynh [6 ]
Pham, Hung Nhu
Cao, Son Luong [7 ]
Hoang, Sy Van [8 ,9 ]
机构
[1] Bach Mai Hosp, Vietnam Natl Heart Inst, Hanoi, Vietnam
[2] Hanoi Med Univ, Hanoi, Vietnam
[3] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[4] Nhan Dan Gia Dinh Hosp, Ho Chi Minh City, Vietnam
[5] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[6] Hanoi Heart Hosp, Hanoi, Vietnam
[7] Univ Med Ctr Ho Chi Minh City, Dept Cardiol, Ho Chi Minh City, Vietnam
[8] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[9] Univ Med & Pharm Ho Chi Minh City, Ho Chi Minh City, Vietnam
关键词
Rivaroxaban; AF; acute kidney injury; renal failure; anticoagulant -related nephropathy; CHRONIC KIDNEY-DISEASE; CLINICAL-TRIALS; OUTCOMES; RISK; ANTICOAGULANTS; WARFARIN; DECLINE; INJURY;
D O I
10.15420/ecr.2024.07
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: AF is a global health concern, with systemic complications including renal dysfunction. This systematic review and meta-analysis compares the effects of rivaroxaban, a Factor Xa inhibitor, and vitamin K antagonists (VKAs) on renal outcomes in AF patients. Methods: The study protocol is registered in PROSPERO (ID: CRD42023462756). We systematically searched the PubMed, Embase and Cochrane Library databases from 1 January 2017 to 30 June 2023 for real-world studies comparing the effects of rivaroxaban and VKAs on renal outcomes in AF patients, including acute kidney injury, a >= 30% decrease in estimated glomerular filtration rate, doubling of serum creatinine and worsening renal function. Subgroup analyses targeted diabetes, pre-existing kidney disease, the elderly (age >= 65 years) and Asian populations. The risk of bias was assessed used the Robins-I tool. HRs and 95% CIs were synthesised through a random-effects model. Two sensitivity analyses were performed, using a fixed-effects model and excluding conference abstracts. Results: We identified 1,666 records. After screening, 14 studies comparing rivaroxaban and VKAs were included. Rivaroxaban exhibited superiority over VKAs in preventing: acute kidney injury (HR 0.68; 95% CI [0.61-0.77]; p<0.00001); a >= 30% decrease in estimated glomerular filtration rate (HR 0.71; 95% CI [0.60-0.84]; p<0.0001); doubling of serum creatinine (HR 0.50; 95% CI [0.36-0.70]; p<0.0001); and worsening renal function (HR 0.56; 95% CI [0.45-0.69]; p<0.00001). Subgroup and sensitivity analyses consistently confirmed rivaroxaban's favourable effects on renal outcomes in diabetes, pre-existing kidney disease, the elderly and Asian populations. Conclusion: Our findings support the preference of rivaroxaban over VKAs for renal outcomes in AF. The findings endorse rivaroxaban as the preferred anticoagulant to mitigate renal complications, offering clinicians valuable insights for tailored strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Dabigatran in Real World of Atrial Fibrillation: Systematic Review and Meta-analysis of Comparison Studies With Vitamin K Antagonists
    Carmo, Joao
    Costa, Francisco M.
    Ferreira, Jorge
    Mendes, Miguel
    CIRCULATION, 2015, 132
  • [2] Safety of Rivaroxaban versus Vitamin K Antagonists: A Systematic Review and Meta-Analysis
    Wasserlauf, Guila
    Grandi, Sonia M.
    Filion, Kristian B.
    Eisenberg, Mark J.
    CIRCULATION, 2012, 126 (21)
  • [3] ASSESSING RENAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS WITH PRE-EXISTING RENAL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RIVAROXABAN VERSUS VITAMIN K ANTAGONISTS
    Hoang Van Sy
    Minh Ton That
    Ho Huynh Quang Tri
    Hai Hoang Nguyen
    Son Luong Cao
    Song Giang Tran
    Hung Manh Pham
    Phong Dinh Phan
    Pham, Hung N.
    Quynh Nga Vu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 76 - 76
  • [4] Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Systematic Review and Meta-Analysis
    Bai, Ying
    Deng, Hai
    Shantsila, Alena
    Lip, Gregory Y. H.
    STROKE, 2017, 48 (04) : 970 - 976
  • [5] Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review
    Briere, Jean-Baptiste
    Bowrin, Kevin
    Coleman, Craig
    Fauchier, Laurent
    Levy, Pierre
    Folkerts, Kerstin
    Toumi, Mondher
    Taieb, Vanessa
    Millier, Aurelie
    Wu, Olivia
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (01) : 27 - 36
  • [6] Dabigatran in real-world atrial fibrillation Meta-analysis of observational comparison studies with vitamin K antagonists
    Carmo, Joao
    Costa, Francisco Moscoso
    Ferreira, Jorge
    Mendes, Miguel
    THROMBOSIS AND HAEMOSTASIS, 2016, 116 (04) : 754 - 763
  • [7] Benefits and Harms of Low-Dose Rivaroxaban in Asian Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-World Studies
    Qian, Jun
    Yan, Yi-Dan
    Yang, Sheng-Yan
    Zhang, Chi
    Li, Wen-Yan
    Gu, Zhi-Chun
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [8] Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
    Ntaios, George
    Papavasileiou, Vasileios
    Makaritsis, Konstantinos
    Vemmos, Konstantinos
    Michel, Patrik
    Gregory, Y. H.
    STROKE, 2017, 48 (09) : 2494 - +
  • [9] Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review
    Deitelzweig, Steve
    Lip, Gregory Y. H.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 243 - 244
  • [10] RIVAROXABAN REDUCES THE RISK OF RENAL ADVERSE OUTCOMES COMPARED WITH VITAMIN K ANTAGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION - RESULTS FROM A SYSTEMATIC REVIEW AND META-ANALYSIS
    Pham, Hung Manh
    Sy, Hoang Van
    Tri, Ho Huynh Quang
    That, Minh Ton
    Phan, Phong Dinh
    Nguyen, Hai Hoang
    Tran, Song Giang
    Cao, Son Luong
    Vu, Quynh Nga
    Pham, Hung N.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 11 - 11